Table 1 Immunobridging analysis using a logistic regression model based on data from NHPs vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in a 56-day interval; PPI analysis set.

From: Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola

Participants Vaccinated, N

764

Pre-planned Immunobridging Analysis

 

 Mean Predicted Survival Probability, % (95% CI)

53.4 (36.7–67.4)

Post-hoc Analysis

 

 Mean Predicted Survival Probability, % (98.7% CI)

53.4 (33.8–70.9)

 O’Brien-Fleming Adjustment (One-sided Alpha of 0.0066)

 
  1. CI confidence interval, NHP non-human primate, PPI per-protocol immunogenicity.
  2. This analysis was based on the pooled data of healthy adults (aged 18-50 years) vaccinated with Ad26.ZEBOV, MVA-BN-Filo in a 56-day interval in five clinical studies (EBL2001, EBL2002, EBL3001, EBL3002, and EBL3003) using a logistic regression model based on NHP data from the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in a 56-day interval.
Back to article page